The Oncology Institute Expects FY2025 Revenue Of $460M-$480M Vs. Consensus Of $482.80M
Author: Benzinga Newsdesk | March 24, 2025 05:13am
2025 Guidance
Revenue
$460 to $480 million
Gross Profit
$73 to $82 million
Adjusted EBITDA
$(8) to $(17) million
Free Cash Flow
$(12) to $(21) million
The Company expects Adjusted EBITDA of approximately $(5) to $(6) million in the first quarter of 2025 primarily due to seasonal factors such as new year drug price increases and lower encounter volumes.
